Skip to main content
SpringerLink
Log in

Biochemical markers of bone metabolism in the assessment of osteoporosis: Useful or not?

  • Opinion
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Seibel M.J. Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporosis 2000, 11: 18–29.

    Article  CAS  Google Scholar 

  2. Seibel M., Woitge H., Scheidt N.C., et al. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. J. Bone Miner. Res. 1994, 9: 1433–1440.

    Article  PubMed  CAS  Google Scholar 

  3. Schneider D.L., Barrett-Connor E.L. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density. Arch. Intern. Med. 1997, 157: 1241–1245.

    Article  PubMed  CAS  Google Scholar 

  4. Akesson K., Ljunghall S., Jonsson B., et al. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: A retrospective and prospective population-based study in women. J. Bone Miner. Res. 1995, 10: 1823–1829.

    Article  PubMed  CAS  Google Scholar 

  5. Chesnut C.H. III, Bell N.H., Clark G.S., et al. Hormone replacement therapy in postmenopausal women: Urinary Ntelopeptide of type I collagen monitors therapeutic effcet and predicts response of bone mineral density. Am. J. Med. 1997, 102: 29–37.

    Article  PubMed  CAS  Google Scholar 

  6. Dresner-Pollak R., Seibel M.J., Greenspan S., et al. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif. Tissue Int. 1996, 59: 328–333.

    Article  PubMed  CAS  Google Scholar 

  7. Ross P.D., Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J. Bone Miner. Res. 1998, 13: 297–302.

    Article  PubMed  CAS  Google Scholar 

  8. Riggs B.L., Melton L.J. III, O’Fallon W.M. Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 1996, 18: 197S–201S.

    Article  PubMed  CAS  Google Scholar 

  9. Van Daele P.L., Seibel M.J., Burger H., et al. Case control analysis of bone resorption markers, disability and hip fracture risk: the Rotterdam study. Br. Med. J. 1996, 312: 482–483.

    Article  Google Scholar 

  10. Weel A., Seibel M.J., Pols H.A.P. et al. Bone resorption and risk of non-vertebral fractures — a populations based study: The Rotterdam study. 2002, in press.

    Google Scholar 

  11. Garnero P., Hausherr E., Chapuy M.C., et al. Markers of bone resorption predict hip fractures in elderly women. The EPIDOS study. J. Bone Mineral Res. 1996, 11: 1531–1538.

    Article  CAS  Google Scholar 

  12. Civitelli R., Gonnelli S., Zacchei F., et al. Bone turnover in postmenopausal osteoporosis. J. Clin. Invest. 1988, 82: 1268–1274.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  13. Nielsen N.M., Von der Recke P., Hansen M.A., Overgaard K., Christensen C. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers. Calcif. Tissue Int. 1994, 55: 8–11.

    Article  PubMed  CAS  Google Scholar 

  14. Gonnelli S., Cepollaro C., Pondrelli C., et al. Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif. Tissue Int. 1999, 65: 359–364.

    Article  PubMed  CAS  Google Scholar 

  15. Rosen C., Chesnut C.H. III, Mallinak N.J.S. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J. Clin. Endocrinol. Metab. 1997, 82: 1904–1910.

    PubMed  CAS  Google Scholar 

  16. Seibel M.J., Barton I., Grauer A. Vertebral fracture incidence in postmenopausal osteoporotic women treated with Risdronate: The role of pre-treatment bone turnover. Acta Orthop. Scand. 2002, 46 (Suppl.1): 148.

    Google Scholar 

  17. Meunier P.J., Confavreux E., Tupinon I., Hardouin C., Delmas P.D. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double blind, placebo controlled study and 1-year follow-up). J. Clin. Endocrinol. Metab. 1997, 82: 2784–2791.

    PubMed  CAS  Google Scholar 

  18. Thiebaud D., Burckhardt P., Kriegbaum H., et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am. J. Med. 1997, 103: 298–307.

    Article  PubMed  CAS  Google Scholar 

  19. Reid I.R., Brown J.P., Burckhardt P., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 2002, 346: 653–661.

    Article  PubMed  CAS  Google Scholar 

  20. Bjarnason N.H., Sarkar S., Duong T., Mitlak B., Delmas P.D., Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos. Int. 2001, 12: 922–930.

    Article  PubMed  CAS  Google Scholar 

  21. Eastell R., Barton I., Hannon R.A., et al. Anti-fracture efficacy of Risedronate: Prediction by change in bone resorption markers. Osteoporos. Int. 2002, 13: O42 (Abstract).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Concord Repatriation General Hospital, University of Sidney, Sidney, Australia

    Markus J. Seibel (Chair of Endocrinology, Director of Bone Research Program)

  2. ANZAC Research Program and Department of Endocrinology, Concord Repatriation General Hospital, University of Sidney, Concord Campus, Sydney, NSW 2139, Australia

    Markus J. Seibel (Chair of Endocrinology, Director of Bone Research Program)

  3. Department of Endocrinology and Metabolism, Concord Repatriation General Hospital, University of Sidney, Sidney, Australia

    Markus J. Seibel (Chair of Endocrinology, Director of Bone Research Program)

Authors
  1. Markus J. Seibel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus J. Seibel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seibel, M.J. Biochemical markers of bone metabolism in the assessment of osteoporosis: Useful or not?. J Endocrinol Invest 26, 464–471 (2003). https://doi.org/10.1007/BF03345204

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345204

Key-words

Search

Navigation